Molecular MRI True Cancer Detection is Here

Changing Suspicion into Certainty

At Imagion Biosystems, we’re on a mission to advance image-based cancer detection by combining the precision of molecular targeting with the resolution of MRI.

Now Seeing is Believing

Imagine having the same kind of molecular specificity used in pathology to non-invasively assess “suspicious” lesions or abnormal tissue.

Our MagSense^® imaging agents combine magnetic nanoparticles that produce MR contrast with tumor targeting molecules that bind only to the targeted cancer cells – producing and identifiable contrast pattern detectable in MRI scans.

By integrating the use of molecular biomarkers with high-resolution MRI, MagSense® imaging agents offer radiologists a measure of certainty when combined with the anatomical assessment that is not available with standard MRI protocols or non-specific contrast agents.

Pre & Post-Dose Scans with MagSense^®

(Click to enlarge images)

Clinical Utility of MagSense^®

MagSense^® imaging agents have been developed for multiple types of cancer using known cancer-specific biomarkers.

HER2 Breast Cancer

The MagSense^® HER2 imaging agent uses an anti-HER2 antibody to target HER2+ breast cancer nodal metastases.

Rather than rely on axillary ultrasound to identify suspicious nodes for biopsy, the MagSense^® HER2 imaging agent shows a different contrast in involved nodes compared to normal nodes.

Prostate Cancer

The MagSense^® PSMA imaging agent uses the same PSMA peptide currently being used with PET tracers, providing the same specificity, but eliminating the patient’s exposure to radiation.

With the MagSense^® PSMA imaging agent, MRI can be a primary tool for non-invasive detection of prostate cancer with the benefit of reducing unnecessary biopsies and providing a targeted approach to MRI-guided biopsy.

Ovarian Cancer

The MagSense^® FR imaging agent targets the folate receptor prevalent in ovarian cancer. The current standard of “watchful waiting” by ultrasound too often results in late stage detection.

Molecular MRI offers the opportunity to detect ovarian cancer at earlier stages when there are more treatment options and outcomes are better.

Help Drive the Future of Molecular MRI

The Phase 1 study of the MagSense^® HER2 Imaging Agent was a first-of-its-kind in using a targeted imaging agent with MRI in human subjects. Results were presented at the San Antonio Breast Cancer Symposium.

Now, we are looking for investigators who are interested in being part of making molecular MRI a reality. Our sponsored Phase 2 clinical study will evaluate the prospective diagnostic performance of the MagSense^® imaging agent to detect nodal metastases in women with HER2-positive breast cancer.

Key Objectives in Phase 2

- Optimize MRI sequences and protocol including determining the optimal timing for post-dose imaging
- Establish preliminary patient level concordance of nodal assessment by MagSense imaging to SOC
- Continue safety assessment in a broader patient population

Investigators participating in the Phase 2 study will be making a significant contribution towards validating molecular MRI as a viable diagnostic imaging tool and paving the way for regulatory approval of a technology that could change the way we see cancer.

Help Drive the Future of Molecular MRI

Key Objectives in Phase 2

- Optimize MRI sequences and protocol including determining the optimal timing for post-dose imaging
- Establish preliminary patient level concordance of nodal assessment by MagSense imaging to SOC
- Continue safety assessment in a broader patient population

How MagSense^® Technology Works

MagSense^® imaging agents are bio-conjugated magnetic nanoparticles that selectively bind to tumor biomarkers—in this case, HER2 receptors on breast cancer cells.

Once administered, these particles bind to specific cancer cells, creating a distinct change in MRI signal, providing concrete evidence of tumor for the radiologist.

- Targeted: Delivers high specificity with low systemic toxicity
- Non-invasive: Reduces need for surgical biopsy
- MRI-Compatible: No additional hardware or novel equipment needed

This platform has the potential to open up new frontiers in molecular imaging—making cancer detection smarter, safer, and more precise.

Become an Investigator

We’re seeking experienced radiologists and imaging specialists to join our clinical study as Investigators.

If you’re passionate about advancing non-invasive diagnostics, this is a unique opportunity to be part of a groundbreaking innovation at the forefront of precision imaging.

*Sites must be equipped for MRI and capable of enrolling HER2+ breast cancer patients.

Become an Investor

Imagion Biosystems offers a unique investment opportunity. Unlike most biotech companies that are funded by venture capital, Imagion is a publicly traded company which presents everyday investors a rare opportunity to get involved directly—and meaningfully.

This is your chance to support a safer, smarter future for cancer care in your field. As we advance our clinical programs, your investment helps accelerate access to non-invasive, biopsy-free detection technologies that can truly change lives.

Join us at the forefront of innovation—and make your impact count.

Learn more about investing in IBX →

Express your interests and let us know how you'd like to connect.

We respect your inbox—we’ll only send updates relevant to your interests.

Questions? Email our team: info@imagionbio.com

Molecular MRI True Cancer Detection is Here

Now Seeing is Believing

Pre & Post-Dose Scans with MagSense^®